Chief Executive Officer
Timothy M. Ruane joined InSite Vision, a SUN PHARMA company on December 1, 2010. Prior to InSite Vision, he served as President and Chief Executive Officer of Tekmira Pharmaceuticals Corporation and INEX Pharmaceuticals Corporation (which spun-out Tekmira in 2007) from 2005 until June 2008. Under his leadership, the company closed a four-party transaction to create a leader in the siRNA field, implemented a global licensing agreement to enable systemic RNAi-based therapies, and successfully partnered three liposomal chemotherapy products. From 2004 to 2005, he was Senior Vice President of Corporate Development with INEX. Prior to INEX, he served as a senior vice president at ILEX Oncology responsible for business management; ILEX was acquired by Genzyme in 2004. Mr. Ruane was the Marketing Director of Oncology for North and South America for Pharmacia Corporation; Pharmacia was acquired by Pfizer in 2002. Mr. Ruane was also Director of Marketing at Immunex Corporation.
Mr. Ruane has a Bachelor of Science degree in Business Finance from Wake Forest University and an Executive Master of Business Administration degree from the University of Washington. He is married, and he and his wife of 17 years - Jennifer - recently adopted twin infants (boy and girl).